Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial-Reference-Cited by-同舟云学术

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

Published:2011-04 Issue:4 Volume:11 Page:284-292
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Marty Francisco M,Ljungman Per,Papanicolaou Genovefa A,Winston Drew J,Chemaly Roy F,Strasfeld Lynne,Young Jo-Anne H,Rodriguez Tulio,Maertens Johan,Schmitt Michael,Einsele Hermann,Ferrant Augustin,Lipton Jeffrey H,Villano Stephen A,Chen Hongzi,Boeckh Michael

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference32 articles.

1. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies;Boeckh;Biol Blood Marrow Transplant,2003

2. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study;Boeckh;Blood,1996

3. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation;Einsele;Blood,1995

4. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant;Goodrich;Ann Intern Med,1993

5. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial;Winston;Ann Intern Med,1993

Cited by 313 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol (Maribavir IIR);2024-09-04

2. Cytomegalovirus in haematopoietic cell transplantation - The troll is still there;Best Practice & Research Clinical Haematology;2024-09

3. UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.;Mediterranean Journal of Hematology and Infectious Diseases;2024-08-31

4. Efficacy of the drug maribavir according to clinical studies;Clinical Medicine (Russian Journal);2024-05-07

5. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12